Tick-borne relapsing fever

Summary

Tick-borne relapsing fever (MONDO:0001621) is a disease and 2 clinical trials. Top therapeutic interventions include doxycycline anhydrous. A subtype of Rickettsiosis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	tick-borne relapsing fever
Mondo ID	MONDO:0001621
DOID	DOID:13036
ICD-10-CM	A68.1
ICD-11	923521593
NCIT	C34976
SNOMED CT	10301003
UMLS	C0035022
MedGen	20515
GARD	0022977
Is cancer (heuristic)	no

Also known as: Relapsing fever, tick-borne

Disease family

This is a subtype of Rickettsiosis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › bacterial infectious disease › Rickettsiosis › tick-borne relapsing fever

Related subtypes (2): Anaplasmataceae infectious disease, Rickettsiaceae infectious disease

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2/PHASE3	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00237016	PHASE2/PHASE3	COMPLETED	Post Exposure Treatment With Doxycycline for the Prevention of Relapsing Fever
NCT06045481	Not specified	NOT_YET_RECRUITING	Postexposure Prophylaxis With Single Dose Doxycycline for the Prevention of Tick-borne Relapsing Fever

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DOXYCYCLINE ANHYDROUS	4	3